
Quarterly report 2026-Q1
added 04-28-2026
OPKO Health Long-Term Debt 2011-2026 | OPK
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt OPKO Health
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 M | 7.73 M | 9.29 M | 205 M | 226 M | 260 M | 167 M | 135 M | 83.2 M | 124 M | 134 M | 215 M | 5.15 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 260 M | 3 M | 121 M |
Quarterly Long-Term Debt OPKO Health
| 2026-Q1 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.01 M | 2.77 M | 2.83 M | 3.53 M | 3.68 M | 4.04 M | 7.93 M | 8.5 M | 245 M | 9.29 M | 245 M | - | 230 M | 205 M | 1.67 M | 3.97 M | 3.32 M | 3.84 M | 4.01 M | 3.84 M | 3.84 M | 3.91 M | 4.09 M | 3.91 M | 3.91 M | 4.65 M | 4.65 M | 4.65 M | 4.65 M | 1.57 M | 1.57 M | 1.57 M | 1.57 M | 717 K | 717 K | 717 K | 717 K | 2.52 M | 2.52 M | 2.52 M | 2.52 M | 2.43 M | 2.43 M | 2.43 M | 2.43 M | 3.27 M | 3.27 M | 3.27 M | 3.27 M | 5.15 M | 5.15 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 245 M | 717 K | 21.6 M |
Long-Term Debt of other stocks in the Diagnostics research industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Castle Biosciences
CSTL
|
9.64 M | $ 20.15 | -1.9 % | $ 584 M | ||
|
Centogene N.V.
CNTG
|
15.6 M | - | -6.23 % | $ 30.6 M | ||
|
Heska Corporation
HSKA
|
307 K | - | - | $ 1.31 B | ||
|
Guardant Health
GH
|
1.5 B | $ 118.95 | 0.8 % | $ 14.9 B | ||
|
Fulgent Genetics
FLGT
|
360 K | $ 17.11 | -1.55 % | $ 517 M | ||
|
ICON Public Limited Company
ICLR
|
3.4 B | $ 116.78 | 0.18 % | $ 9.63 B | ||
|
Agilent Technologies
A
|
2.73 B | $ 114.96 | 0.15 % | $ 34.9 B | ||
|
Celcuity
CELC
|
138 M | $ 138.23 | -3.02 % | $ 6.46 B | ||
|
Co-Diagnostics
CODX
|
574 K | $ 5.07 | 36.66 % | $ 6.74 M | ||
|
Akumin
AKU
|
1.25 B | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
1.04 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
30 K | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
1.2 M | - | -13.05 % | $ 7.29 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
32 K | - | - | $ 562 M | ||
|
CareDx, Inc
CDNA
|
19.7 M | $ 21.63 | 0.28 % | $ 1.15 B | ||
|
Chembio Diagnostics
CEMI
|
76.7 K | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
16 K | - | - | $ 9.42 M | ||
|
HTG Molecular Diagnostics
HTGM
|
546 K | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
554 M | $ 144.41 | -0.29 % | $ 23 B | ||
|
Interpace Biosciences
IDXG
|
752 K | $ 1.82 | 1.11 % | $ 8.05 M | ||
|
Lantheus Holdings
LNTH
|
569 M | $ 103.0 | 9.03 % | $ 6.95 B | ||
|
Medpace Holdings
MEDP
|
114 M | $ 432.8 | 0.63 % | $ 12.5 B | ||
|
Global Cord Blood Corporation
CO
|
147 K | - | - | $ 399 M | ||
|
Mettler-Toledo International
MTD
|
2.09 B | $ 1 103.09 | 1.16 % | $ 22.7 B | ||
|
Fluidigm Corporation
FLDM
|
54.2 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
22.9 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
5.49 M | - | 0.12 % | $ 80.1 M | ||
|
DermTech
DMTK
|
38 K | - | -11.32 % | $ 2.94 M | ||
|
Charles River Laboratories International
CRL
|
2.14 B | $ 160.3 | 0.91 % | $ 7.95 B | ||
|
Personalis
PSNL
|
621 K | $ 8.47 | 2.67 % | $ 756 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.16 B | - | - | $ 10.7 B | ||
|
Enzo Biochem
ENZ
|
189 K | - | -8.98 % | $ 14.8 K | ||
|
NeoGenomics
NEO
|
342 M | $ 9.23 | 1.32 % | $ 1.18 B | ||
|
Exact Sciences Corporation
EXAS
|
6.4 M | - | - | $ 19.8 B | ||
|
National Research Corporation
NRC
|
75 M | $ 19.08 | 0.21 % | $ 427 M | ||
|
Natera
NTRA
|
282 M | $ 203.19 | -0.25 % | $ 20 B | ||
|
Myriad Genetics
MYGN
|
120 M | $ 3.82 | -2.3 % | $ 354 M | ||
|
Koninklijke Philips N.V.
PHG
|
5.7 B | $ 26.95 | -0.74 % | $ 25.6 B | ||
|
Senseonics Holdings
SENS
|
35.6 M | $ 6.34 | 2.92 % | $ 265 M | ||
|
QIAGEN N.V.
QGEN
|
1.65 B | - | - | $ 10.6 B | ||
|
Twist Bioscience Corporation
TWST
|
61.8 M | $ 60.57 | 2.95 % | $ 3.62 B | ||
|
Soleno Therapeutics
SLNO
|
49.9 M | - | - | $ 2.69 B | ||
|
Biomerica
BMRA
|
100 K | $ 2.49 | 2.05 % | $ 5.72 M | ||
|
Laboratory Corporation of America Holdings
LH
|
5.08 B | $ 259.93 | 1.63 % | $ 21.6 B | ||
|
Thermo Fisher Scientific
TMO
|
39.2 B | $ 448.28 | -0.24 % | $ 169 B | ||
|
Trinity Biotech plc
TRIB
|
82.7 M | $ 0.6 | -3.7 % | $ 216 M | ||
|
Motus GI Holdings
MOTS
|
1.24 M | - | -34.28 % | $ 263 K | ||
|
Neogen Corporation
NEOG
|
875 M | $ 8.9 | 0.45 % | $ 1.93 B | ||
|
Waters Corporation
WAT
|
947 M | $ 342.37 | 0.4 % | $ 20.4 B | ||
|
Quest Diagnostics Incorporated
DGX
|
5.17 B | $ 195.21 | 0.72 % | $ 21.7 B |